Notas de Prensa  

01 de junio de 2003

Aranesp Dosed Once Every Two Weeks Increases Hemoglobin Levels, Improves Fatigue And Reduces Need For Transfusions In Patients With Chemotherapy-Induced Anemia


CHICAGO, IL, June 1, 2003 - Amgen (Nasdaq:AMGN), the world´s largest biotechnology company, presented data on Aranesp?? (darbepoetin alfa) dosed once every two weeks and once every three weeks in the management of anemia in patients with chemotherapy-induced anemia. Results from seven studies, including the large-scale SOAR (Successful Outcomes in Anemia Research) trial, further enhance the wide body of data supporting the benefits of extended dosing with Aranesp?? compared to other currently available anemia treatments.


Subir notas de prensa y convocatorias

Próximas convocatorias   

Ver todas


Busca notas de prensa por especialidad médica o enfermedad.

Ver todas


Busca notas de prensa por su fecha de edición.

  Selecciona el año

Copyright © 2018, Farmavet, S.L. Todos los derechos reservados.